Who would've thought? Mosa Meat and AcuSurgical paving the path for the future.
NRW.BANK.Venture Fonds joins Semalytix with 2mil EUR
As part of an expanded Series A financing round, NRW.BANK is participating in Semalytix with its Venture Fund.
The Bielefeld start-up has developed an artificial intelligence-based platform 'Pharos' for systematic research into patient needs.
The aim is to record the treatment experience of patients, uncover unknown side effects and thus improve future generations of drugs. With the investment, the company wants to expand its software and services and further expand its market position.
https://www.pressebox.de/inaktiv/nrwbank/NRW-BANK-Venture-Fonds-beteiligt-sich-mit-2-Millionen-Euro-an-Semalytix/boxid/1045404Mosa Meat raises $ 85 million in 3rd investment round
Dutch cultured meat manufacturer Mosa Meat has raised a total of $ 85 million in the third and final closing of the Series B funding round.
Investers are amongst others Nutreco, a global leader in animal nutrition and aquafeed, and Jitse Groen, CEO of Just Eat Takeaway.com.
Mosa meat will use the funds to extend the current pilot production facility in Maastricht (NL), develop an industrial-sized production line, expand the team, and introduce cultivated beef to consumers.
Mosa Meat raises $ 85 million in 3rd investment round - IO
Mosa meat will use the funds to extend the current pilot production facility in Maastricht (NL) and develop an industrial-sized production line.
AcuSurgical Raises €5.75M in Series A Financing
AcuSurgical, a Montpellier, France-based-based company focused on robotic microsurgery, raised €5.75m in Series A financing.
The round was led by Mérieux Equity Partners (via OMX Europe Venture Fund) and Supernova Invest (via Supernova 2 Fund), with Sofimac Innovation (via Pertinence Invest 2 Fund) and IRDI Capital Investissement (via Irdinov 2 and Inn’Vest PME Occitanie Est Funds) participating.
The company intends to use the funds to conduct clinical trials and reach regulatory approval with vitreo-retinal surgery as the first indication.
AcuSurgical Raises €5.75M in Series A Financing - FinSMEs
AcuSurgical, a Montpellier, France-based-based company focused on robotic microsurgery, raised €5.75m in Series A financing
**ABclonal Biotechnology Closes $93M Series C Financing
ABclonal Biotechnology, a Woburn, Mass.-based global life science tools and services provider, completed its $92.9m Series C financing.
The round was led by Sequoia Capital China and LYFE Capital, with participation from Sigma Square Capital, Kinghall Ventures, and Lucion Capital.
The company intends to use the funds to accelerate its research and development pipeline for in vitro diagnostic raw materials and expand production capabilities of its research reagent products and services. It is also currently in talks to acquire a contract research organization focused on single-cell-based monoclonal antibody development.
ABclonal Biotechnology Closes $93M Series C Financing - FinSMEs
ABclonal Biotechnology, a Woburn, Mass.-based global life science tools and services provider, completed its $92.9m Series C financing
Elicio Therapeutics Raises $73M in Total Series B Financing
Elicio Therapeutics, a Cambridge, Mass.-based biotechnology company developing a pipeline of potent immunotherapies based on its proprietary lymph node targeting technology, closed a $73m Series B financing.
Led by Robert Connelly, CEO, Christopher Haqq, M.D., Ph.D., Executive Vice President, Head of Research and Development, and Chief Medical Officer, Elicio Therapeutics is advancing the Amphiphile technology across immunotherapy platforms to defeat cancers and infectious diseases.
The company intends to use the funds to advance its lead program ELI-002 into clinical trials in early 2021 for mutated KRAS (mKRAS) driven cancers, estimated to be 25% of all human solid tumors.
Elicio Therapeutics Raises $73M in Total Series B Financing - FinSMEs
Elicio Therapeutics, a Cambridge, Mass.-based biotechnology company developing a pipeline of potent immunotherapies based on its proprietary lymph node targeting technology, closed a $73m Series B financing
Eden Health Raises $60M in Series C Funding
Eden Health, a NYC-based national medical practice, raised $60m in Series C funding.
The round, which brought total funding to $100m, was led by Insight Partners, with participation from Amigos Health, Aspect Ventures, Company Ventures, Flare Capital, Flexcap Ventures, Max Ventures and PJC.
The company intends to use the funds to extend its Virtual Care platform, expand its brick-and-mortar medical office presence to several new major U.S. metropolitan areas, and build new features that allow for integrations of third-party healthcare services.
